WeTrials
Recruiting

A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

What is this study?

This study is testing a new combination of two medications, All-Trans Retinoic Acid and Retifanlimab, for adults with a type of brain tumor called an IDH-mutant glioma that has returned after previous treatments. Researchers hope this combination will be safe and help the body's immune system fight the tumor.

Who can participate?

You may be able to join if you have a confirmed diagnosis of astrocytoma or oligodendroglioma with an IDH gene mutation that has grown after past treatments like chemotherapy or radiation. There are specific rules about tumor location and past medications to keep you safe.

What will happen?

Participants will receive the study medications and have regular check-ups, including MRI scans, to see how the tumor responds and how well the body tolerates the treatment. Your care team will monitor you closely throughout the entire process.

Where and when?

This study is currently recruiting participants and takes place in Philadelphia, Pennsylvania, United States. Talk to your doctor to see if traveling to this location is an option for you.

Key Points
  • 1Tests a combination treatment for returned brain tumors
  • 2Requires a specific genetic mutation called IDH
  • 3Currently actively recruiting participants in Philadelphia

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
GliomaIDH MutationAstrocytomaOligodendroglioma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.